Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sionna Therapeutics (SION) Cash from Financing Activities (2024 - 2026)

Quarterly results put Cash from Financing Activities at $1.9 million for Q1 2026, down 99.06% from a year ago — trailing twelve months through Mar 2026 was $5.2 million (down 97.39% YoY), and the annual figure for FY2025 was $205.7 million, up 14.94%.

Sionna Therapeutics has reported Cash from Financing Activities over the past 3 years, most recently at $1.9 million for Q1 2026.

  • Cash from Financing Activities reached $1.9 million in Q1 2026 per SION's latest filing, up from $1.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $202.4 million in Q1 2025 and bottomed at -$1.4 million in Q4 2024.
  • Median Cash from Financing Activities over the past 3 years was $1.7 million (2025), compared with a mean of $43.0 million.
  • Peak annual rise in Cash from Financing Activities hit 298.19% in 2025, while the deepest fall reached 921.05% in 2025.
  • Over 3 years, Cash from Financing Activities stood at -$1.4 million in 2024, then surged by 217.83% to $1.7 million in 2025, then increased by 14.1% to $1.9 million in 2026.
  • Business Quant data shows Cash from Financing Activities for SION at $1.9 million in Q1 2026, $1.7 million in Q4 2025, and $2.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 7.00 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 53,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -538.80 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -802.20 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 15.71 Mn
10 Sionna Therapeutics 1.87 Bn 1.87 Bn - 1.89 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.89 Mn
Mar 31, 2026 1.89 Mn
Dec 31, 2025 1.66 Mn
Dec 31, 2025 1.66 Mn
Sep 30, 2025 1.97 Mn
Sep 30, 2025 1.97 Mn
Jun 30, 2025 -312,000.00
Jun 30, 2025 -312,000.00
Mar 31, 2025 202.39 Mn
Mar 31, 2025 202.39 Mn
Dec 31, 2024 -1.41 Mn
Dec 31, 2024 -1.41 Mn
Sep 30, 2024 -996,000.00
Sep 30, 2024 -996,000.00
Jun 30, 2024 38,000.00
Jun 30, 2024 38,000.00
Mar 31, 2024 181.33 Mn
Mar 31, 2024 181.33 Mn